147 related articles for article (PubMed ID: 37180670)
1. Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426.
Ichikawa Y; Seki N; Honda T; Sakugawa M; Hosokawa S; Bessho A; Agemi Y; Shimokawa T; Otani S; Nakahara Y; Naoki K; Yomota M; Hosomi Y; Takiguchi Y; Tokito T; Ando S; Okamoto H
Transl Cancer Res; 2023 Apr; 12(4):873-886. PubMed ID: 37180670
[TBL] [Abstract][Full Text] [Related]
2. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting.
Tamiya A; Tamiya M; Inagaki Y; Taniguchi Y; Nakao K; Matsuda Y; Kawamura T; Kunimasa K; Inoue T; Nishino K; Okishio K
Anticancer Res; 2023 Mar; 43(3):1325-1330. PubMed ID: 36854522
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
Tamiya M; Tamiya A; Suzuki H; Taniguchi Y; Katayama K; Minomo S; Nakao K; Takeuchi N; Matsuda Y; Naito Y; Shiroyama T; Okamoto N; Okishio K; Kumagai T; Atagi S; Imamura F; Hirashima T
Invest New Drugs; 2021 Aug; 39(4):1106-1112. PubMed ID: 33544282
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TORG1322.
Zenke Y; Niho S; Umemura S; Ishihara M; Seki N; Nogami N; Hosomi Y; Shimokawa T; Tokito T; Goto Y; Miura Y; Saito H; Hida N; Ikeda S; Tanaka H; Furuya N; Misumi T; Yamanaka T; Ohe Y; Okamoto H
Lung Cancer; 2020 Aug; 146():182-188. PubMed ID: 32559454
[TBL] [Abstract][Full Text] [Related]
6. Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC.
Katsurada N; Tachihara M; Hatakeyama Y; Koyama K; Yumura M; Kiriu T; Dokuni R; Hazama D; Tokunaga S; Tamura D; Nakata K; Yamamoto M; Kamiryo H; Kobayashi K; Tanaka Y; Maniwa Y; Nishimura Y
Cancer Manag Res; 2020; 12():777-782. PubMed ID: 32099473
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.
Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T
J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970
[TBL] [Abstract][Full Text] [Related]
8. A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114).
Sakashita H; Uchibori K; Jin Y; Tsutsui T; Honda T; Sakakibara R; Mitsumura T; Nukui Y; Shirai T; Masuo M; Suhara K; Furusawa H; Yamashita T; Ohba T; Saito K; Takagiwa J; Miyashita Y; Inase N; Miyazaki Y
Thorac Cancer; 2022 May; 13(9):1267-1275. PubMed ID: 35322551
[TBL] [Abstract][Full Text] [Related]
9. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer.
Nakashima K; Akamatsu H; Murakami H; Niwa T; Iwamoto Y; Ozawa Y; Yokoyama T; Shoda H; Yamamoto N; Yoshioka H; Masuda K; Naito T; Mori K; Takahashi T
Anticancer Res; 2019 Mar; 39(3):1463-1468. PubMed ID: 30842183
[TBL] [Abstract][Full Text] [Related]
11. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
Nakao A; Uchino J; Igata F; On R; Ikeda T; Yatsugi H; Hirano R; Sasaki T; Tanimura K; Imabayashi T; Tamiya N; Kaneko Y; Yamada T; Nagata N; Watanabe K; Kishimoto J; Takayama K; Fujita M
Invest New Drugs; 2018 Oct; 36(5):903-910. PubMed ID: 29846848
[TBL] [Abstract][Full Text] [Related]
12. Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Tsuchiya-Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I
Oncologist; 2020 Jun; 25(6):475-e891. PubMed ID: 31649134
[TBL] [Abstract][Full Text] [Related]
13. A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Tachihara M; Kiriu T; Hata A; Hatakeyama Y; Nakata K; Nagano T; Yamamoto M; Kobayashi K; Ohnishi H; Katakami N; Nishimura Y
Cancer Manag Res; 2019; 11():7135-7140. PubMed ID: 31534366
[TBL] [Abstract][Full Text] [Related]
14.
Gajra A; Karim NA; Mulford DA; Villaruz LC; Matrana MR; Ali HY; Santos ES; Berry T; Ong TJ; Sanford A; Amiri K; Spigel DR
Front Oncol; 2018; 8():253. PubMed ID: 30087850
[TBL] [Abstract][Full Text] [Related]
15. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol.
Kogure Y; Saka H; Takiguchi Y; Atagi S; Kurata T; Ebi N; Inoue A; Kubota K; Takenoyama M; Seto T; Kada A; Yamanaka T; Ando M; Yamamoto N; Gemma A; Ichinose Y
Clin Lung Cancer; 2018 Sep; 19(5):e711-e715. PubMed ID: 29861395
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer.
Okuma Y; Hosomi Y; Takahashi S; Nakahara Y; Watanabe K; Nagamata M; Takagi Y; Mikura S
Cancer Chemother Pharmacol; 2016 Aug; 78(2):383-8. PubMed ID: 27339149
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
Kogure Y; Iwasawa S; Saka H; Hamamoto Y; Kada A; Hashimoto H; Atagi S; Takiguchi Y; Ebi N; Inoue A; Kurata T; Okamoto I; Yamaguchi M; Harada T; Seike M; Ando M; Saito AM; Kubota K; Takenoyama M; Seto T; Yamamoto N; Gemma A
Lancet Healthy Longev; 2021 Dec; 2(12):e791-e800. PubMed ID: 36098037
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer.
Saito Y; Takekuma Y; Shinagawa N; Sugawara M
Support Care Cancer; 2022 May; 30(5):4081-4088. PubMed ID: 35066667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
